| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 10-Q |
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 10 Sep 2026 |
8-K: Regulation FD Disclosure
This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and cli... |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter |
| 08 Jul 2026 | SCHEDULE 13G |
| 10 Jun 2026 |
Form 4: Baker Bros. Advisors Lp, Director and 5 others
Granted 76,000 Non-Qualified Stock Option (right to buy) |
| 10 Jun 2026 |
Form 4: Dorton Katina, Director
Granted 38,000 Director Stock Option (Right to Buy) |
| 10 Jun 2026 |
Form 4: Babler Martin, Director
Granted 38,000 Director Stock Option (Right to Buy) |
| 10 Jun 2026 |
Form 4: Bonita David P, Director
Granted 38,000 Director Stock Option (Right to Buy) |
| 10 Jun 2026 |
Form 4: Sandor Victor, Director
Granted 38,000 Director Stock Option (Right to Buy) |
| 10 Jun 2026 |
Form 4: Friedman Paul A, Director
Granted 38,000 Director Stock Option (Right to Buy) |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2026, Prelude Therapeutics Incorporated (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") and the following proposals were approved by the Company's stockholders: |
| 12 May 2026 | 10-Q |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) |
| 04 May 2026 |
Form 4: Morris Charles Q, Chief Medical Officer
Granted 450,000 Employee Stock Option (right to buy) ($2.12M) |
| 29 Apr 2026 | ARS |
| 29 Apr 2026 | DEFA14A |
| 29 Apr 2026 |
Proxy statement: annual meeting on June 9, 2026
CEO pay $1.3M, down 42% · say-on-pay vote |
| 28 Apr 2026 | SCHEDULE 13G |
Loading...